OraSure Technologies, Inc. OSUR R2KR3KPHARMA
Company Overview
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.
Recent Developments
- Dec 2025 Revenue of $115.02M (-38.1% YoY); net profit $-68.73M.
- Trailing 12 Months Year-on-year growth — revenue -1.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.54% |
| 1 Year: | -1.90% |
Stock Price Performance
| 1 Year: | +22.11% |
| 6 Months: | +9.09% |
| 3 Months: | -13.86% |
| 1 Month: | -13.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)34.27 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OSUR OraSure Technologies, Inc. R2KR3KPHARMA | 3.48 | -5.04 | $239.59M | 0.00% | -19.81% | -14.07% | 2.54% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 32.55M | 40.18M | 42.31M | - | 41.99M | 43.62M | 45.88M | - | 30.12M | 38.83M | 35.99M | - | 31.60M | 29.26M | 48.01M | 58.58M | 57.61M | 53.92M | 67.71M | 80.23M | 116.46M | 154.96M | 85.44M | 89.19M | 54.13M | 54.34M | 39.91M | - | 29.93M | 31.24M | 27.09M | 26.76M | 27.93M | 30.64M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.63M | 18.08M | 15.31M | 15.79M | 16.12M | - |
| Gross Profit | 20.67M | - | 20.31M | 21.09M | 22.68M | - | 20.31M | 25.48M | 24.64M | - | 24.47M | 25.89M | 28.55M | - | 18.08M | 25.02M | 21.65M | - | 16.13M | 17.26M | 30.29M | 38.33M | 30.67M | 21.47M | 24.30M | 27.80M | 46.51M | 65.81M | 26.37M | 44.34M | 24.07M | 24.69M | 17.07M | - | 12.30M | 13.16M | 11.77M | 10.97M | 11.80M | 13.32M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.56M | 30.45M | 27.49M | 27.82M | 34.98M | - |
| Operating Income | 1.54M | 4.09M | 2.70M | 4.35M | 6.14M | 7.07M | 15.87M | 6.89M | 7.32M | 10.16M | -498.00K | 5.56M | 10.86M | 12.51M | -3.81M | 5.29M | 13.05M | 4.08M | -8.05M | -9.40M | 4.38M | 10.42M | 1.80M | -13.01M | -16.17M | -21.47M | 866.00K | 24.32M | -6.43M | 10.89M | -7.09M | -2.74M | -6.00M | - | -18.27M | -17.29M | -15.71M | -16.85M | -23.18M | 5.44M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.49M | -14.88M | -13.33M | -14.45M | -20.92M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.97M | -16.89M | -13.29M | -18.43M | -21.72M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -456.00K | 2.00M | 47.00K | 210.00K | -432.00K | - |
| Net Income | 1.47M | 4.62M | 2.45M | 3.84M | 6.24M | 7.20M | 12.44M | 5.43M | 5.76M | 7.32M | -2.12M | 4.12M | 8.10M | 10.30M | -3.26M | 4.40M | 13.08M | 2.44M | -7.33M | -10.49M | 1.04M | 3.77M | -1.36M | -15.02M | 27.22M | -18.59M | 5.59M | 27.22M | -4.80M | 11.16M | -3.58M | -615.00K | -4.51M | - | -16.04M | -19.69M | -13.71M | -19.29M | -22.38M | 6.25M |
| Diluted EPS | 0.03 | 0.08 | 0.04 | 0.07 | 0.11 | 0.13 | 0.21 | 0.09 | 0.09 | 0.12 | -0.03 | 0.07 | 0.13 | 0.16 | -0.05 | 0.07 | 0.21 | 0.04 | -0.12 | -0.16 | 0.01 | 0.05 | -0.02 | -0.21 | -0.28 | -0.26 | 0.08 | 0.37 | -0.07 | 0.15 | -0.05 | -0.01 | -0.06 | - | -0.21 | -0.26 | -0.19 | -0.27 | -0.32 | 0.09 |
| R&D Expense | 2.52M | - | 2.37M | 2.98M | 3.20M | - | 2.97M | 3.34M | 3.23M | - | 4.08M | 4.26M | 3.85M | - | 4.37M | 4.54M | 4.62M | - | 5.64M | 6.92M | 8.01M | 8.99M | 7.68M | 8.60M | 8.63M | 9.46M | 10.09M | 10.56M | 7.66M | 8.52M | 7.74M | 6.60M | 5.62M | - | 9.60M | 11.40M | 10.11M | - | 13.65M | 9.44M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.03M | 75.02M | 81.88M | 87.82M | 98.94M | 106.46M | 119.72M | 128.20M | 167.06M | 181.74M | 154.60M | 171.72M | 233.67M | 387.48M | 405.47M | 185.83M | 115.02M |
| Gross Profit | 47.13M | 47.36M | 51.72M | 55.57M | 58.59M | 66.62M | 80.29M | 88.03M | 98.96M | 113.61M | 94.58M | 101.87M | 117.60M | 148.44M | 171.65M | 79.39M | 48.20M |
| Operating Income | -8.79M | -3.35M | -9.40M | -16.27M | -12.16M | -4.80M | 8.06M | 20.27M | 40.24M | 28.43M | 18.61M | -5.18M | -10.16M | -22.16M | 32.68M | -28.25M | -71.97M |
| Net Income | -7.81M | -3.50M | -8.84M | -15.12M | -11.19M | -4.61M | 8.17M | 19.72M | 30.95M | 20.40M | 16.66M | -14.92M | -23.00M | -17.13M | 53.66M | -19.50M | -68.73M |
| Diluted EPS | - | -0.08 | -0.19 | -0.29 | -0.20 | -0.08 | 0.14 | 0.35 | 0.51 | 0.33 | 0.27 | 0.22 | -0.32 | -0.24 | 0.72 | -0.26 | -0.94 |
| R&D Expense | 13.37M | 13.19M | 18.41M | 12.45M | 10.93M | 12.06M | 11.65M | 9.75M | 13.37M | 16.25M | 19.63M | 31.03M | 34.17M | 36.24M | 33.73M | 26.05M | 42.53M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Jan 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 122.52M | 127.86M | 191.44M | - | 184.25M | 189.63M | 189.32M | 207.94M | 296.20M | 315.57M | 349.30M | 454.47M | - | 444.18M | 482.85M | 479.66M | 403.17M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 325.19M | 386.46M | 333.22M | 261.91M |
| Cash & Equivalents | 39.57M | 74.93M | 73.84M | 23.88M | 87.89M | 87.89M | 93.19M | 92.87M | 94.09M | 107.96M | 71.03M | 88.44M | 75.72M | 160.80M | - | 83.98M | 290.41M | 267.76M | 199.28M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 95.70M | 47.61M | 34.20M | 31.06M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 70.80M | 40.17M | 23.82M | 22.20M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | 32.19M | 42.15M | 55.90M | - | 79.75M | 52.17M | 69.32M | 62.34M |
| Current Liabilities | - | - | 19.68M | 21.98M | 16.63M | - | 18.98M | 26.46M | 25.23M | 17.34M | 32.24M | 27.98M | 32.71M | 46.49M | - | 69.06M | 39.54M | 33.48M | 39.80M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.55M | 13.50M | 14.60M | 13.20M |
| Total Equity | 108.33M | 103.81M | 102.84M | 100.25M | 170.31M | 170.31M | 161.15M | 158.70M | 159.44M | 185.85M | 258.08M | 283.38M | 307.14M | 398.57M | - | 364.43M | 430.67M | 410.34M | 340.83M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 72.73M | 73.53M | 74.60M | 70.39M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -292.76K | 3.89M | -2.99M | -5.37M | 8.38M | - | - | 24.60M | 28.16M | 39.09M | 9.80M | 5.81M | -35.38M | -47.20M | 141.58M | 27.37M | -49.02M |
| Investing Cash Flow | 36.90M | -3.77M | -50.34M | -2.02M | -2.46M | - | - | -8.06M | -96.35M | -17.43M | -19.80M | -14.03M | -5.50M | 21.09M | 66.15M | -39.03M | -6.81M |
| Financing Cash Flow | -1.23M | -1.21M | 3.37M | 71.43M | -420.00K | - | - | -1.16M | 30.43M | -1.89M | -4.68M | 92.48M | -2.82M | -3.83M | -3.02M | -4.18M | -16.94M |
| Capital Expenditure | -1.20M | -2.11M | -2.50M | -2.02M | -2.46M | -3.00M | -3.74M | -4.35M | -4.34M | -6.34M | -9.31M | -26.67M | -21.89M | -6.77M | -5.80M | -3.80M | -4.20M |
| Free Cash Flow | -1.49M | 1.78M | -5.50M | -7.39M | 5.92M | - | - | 20.25M | 23.82M | 32.75M | 490.00K | -20.87M | -57.27M | -53.98M | 135.78M | 23.58M | -53.22M |
| Share Buybacks | 700.20K | 709.00K | 909.00K | 1.56M | 829.00K | 639.00K | 6.09M | 3.44M | 1.24M | 3.59M | 3.71M | 2.09M | 2.11M | 2.25M | 0 | 0 | 15.04M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 61.2% | 63.1% | 63.2% | 63.3% | 59.2% | 62.6% | 67.1% | 68.7% | 59.2% | 62.5% | 61.2% | 59.3% | 50.3% | 38.3% | 42.3% | 42.7% | 41.9% |
| Operating Margin % | -11.4% | -4.5% | -11.5% | -18.5% | -12.3% | -4.5% | 6.7% | 15.8% | 24.1% | 15.6% | 12.0% | -3.0% | -4.3% | -5.7% | 8.1% | -15.2% | -62.6% |
| Net Margin % | -10.1% | -4.7% | -10.8% | -17.2% | -11.3% | -4.3% | 6.8% | 15.4% | 18.5% | 11.2% | 10.8% | -8.7% | -9.8% | -4.4% | 13.2% | -10.5% | -59.8% |
| ROE % | -7.5% | -3.4% | -8.8% | -8.9% | -6.9% | -2.9% | 5.1% | 10.6% | 12.0% | 7.2% | 5.4% | -3.7% | - | -4.7% | 12.5% | -4.8% | -20.2% |
| ROCE % | - | -3.3% | -8.9% | -9.3% | -7.4% | -2.9% | 4.9% | 10.6% | 15.2% | 9.9% | 5.9% | -1.3% | - | -5.9% | 7.4% | -6.3% | -19.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.07% | 6.26M | $22.52M |
| 2 | Neuberger Berman Group, LLC | 6.79% | 4.69M | $16.87M |
| 3 | Private Management Group, Inc. | 5.51% | 3.80M | $13.67M |
| 4 | Altai Capital Management, L.p. | 5.24% | 3.61M | $13.01M |
| 5 | Vanguard Capital Management LLC | 4.38% | 3.02M | $10.87M |
| 6 | Systematic Financial Management, L.P. | 4.14% | 2.86M | $10.29M |
| 7 | Dimensional Fund Advisors LP | 3.39% | 2.34M | $8.43M |
| 8 | Acadian Asset Management. LLC | 2.93% | 2.02M | $7.28M |
| 9 | Renaissance Technologies, LLC | 2.92% | 2.01M | $7.25M |
| 10 | Geode Capital Management, LLC | 2.62% | 1.81M | $6.51M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OSUR
OraSure (OSUR) Returns To Profit, But Growth Remains Elusive - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOTm1xX3VfaEJRbjlrRmVwZndSRTF2aXIyOHRkMUpBb2hZbFNiUkQxTW1HbG4xUmpPMGV3cVVxbHVFOWtyU0twdVd5RmJSZnFuU1dpcDVVZk4wS1M3czZEUW9PTGRCNFBwcTJvZjNhSGxIV0JCT3o3Z2ZoLU1mX2RZRHpLV0Y2M2dfSXdZ?o…
BlackRock Inc. Takes $27.91 Million Position in OraSure Technologies, Inc. $OSUR - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxOUWFwZDI4X2Jxb0djSEItd0RGOHR6bFhCZnJwNFZfMWh0bnVqV3N3Vy1uTkhHWmIzNmo1YURuc3AtWmRmcVFKXzVKLWRsV1Zmd1BpRWdGV1BTXzBXZ2w3bktsYndwSzBObndFWnpWX0hMLVgwZjkxMUczVmlENkJWUy1XMFhjdVJuUkhFTk…
OraSure Technologies (OSUR) investor discloses 5.5% stake in common stock - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQQngyaU1EYndRYUZzb2hsRU92RVZ3MHBjV01zRE4xdGtFU2VEN1ZPa1JZUldTVnBUenJnbDByVzdyVDVjbmJMODI3dUVnbHRfQXphVmxiNHVBekdheGt6R18wek1qSWNwSl8tRGFDdHRGX3NBa2ZBTkg1VW9sSnJ2ZEFiOG96TXhpSUctcD…
OraSure Technologies: Lack Of Near Term Catalysts (NASDAQ:OSUR) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNOTVCN080THh3dnJoUkVpQjdYM2h3YWNsN0RYMTVRMm1NYV90NnZsMkNKRVBLRnVvVDA4YmFjbmN6eHAtdERwakV2QjdvQUt4Mjk1bkktaWhHbUl0V1IwVXFwQllGOGJoczBhR2ViaDFtN3hXOXZTcXNZYXRPa3FJaHV3UW1MSjFZNU05UW…
OSUR - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5YbjlHSndZcTM1WW15MzZFWGg0R3R5TVl2c3NTX1lYbXNYeWVOcGFjcWI5V2F0T3I2Z0RjRkhiVThkLUVwZkE?oc=5" target="_blank">OSUR</a> <font color="#6f6f6f">Finviz</font>…
EXCLUSIVE: Altai Capital presses OraSure to sell and give it board seats, letter says - Reuters
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNOWk4TEd4ZTRKcHhVZUE3NkFiNEFiUnNlek5kOWJ2V0tnbUpGc1pJcnhnNG4zQXFSR25Oam5FNnBFMUtVbUhsRE1aNFBBS1lLOG1uSFVYLS1nNGZ2YzN2Ym1HMWp4a1JIN1Y0T3NSTFNZZlIwbzJtZERxSjMtcGFLcFJVTVBZTG41R3M4Qm…
OSUR — Frequently Asked Questions
What is the current share price of OraSure Technologies, Inc. (OSUR)?
As of 2026-09-07 16:24 PDT, OraSure Technologies, Inc. (OSUR) trades at $3.48 on NasdaqGS. Its 52-week range is $2.11 to $4.50.
What is the market capitalisation of OSUR?
OraSure Technologies, Inc. (OSUR) has a market capitalisation of $239.59M on NasdaqGS.
What is the P/E ratio of OSUR?
OSUR trades at a trailing price-to-earnings (P/E) ratio of -5.04. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.90.
What is the return on equity (ROE) of OSUR?
OSUR has a return on equity (ROE) of -14.07%. Its return on capital employed (ROCE) is -19.81%.
Is OSUR a good stock to buy?
This page provides a data-driven analysis of OraSure Technologies, Inc. (OSUR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.